3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
14
NIH
8
OTHER_GOV
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Tongue Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Head and Neck Neoplasms
1
EGFR Positive Non-small Cell Lung Cancer
1
Colorectal Neoplasms
1
Interventions
Sentinel Lymph Node Biopsy
2
Chemoradiotherapy
2
pembrolizumab
1
apatinib
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Positron Emission Tomography Computed Tomography
1
Observation
1
Moxibustion
1
Low-Level Light Therapy
1
Liquid Biopsy
1
Erlotinib Hydrochloride
1
DMAC2L protein, human
1
Control Groups
1
Cisplatin
1
Cetuximab
1
Celecoxib
1
Acupuncture Therapy
1
26S proteasome non-ATPase regulatory subunit 13
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Squamous Cell Carcinoma of Head and Neck
×
Erlotinib Hydrochloride
×
Clear all
NCT02748707
2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2
Unknown
64 enrolled